Compare Recursion Pharmaceuticals Inc (RXRX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs S&P500 ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while S&P500 ETF trades at $764.27. The key difference: S&P500 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SPY | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | — |
52-Week High | $6.79 | $777.82 |
52-Week Low | $2.84 | $631.99 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SPY trades at $766.00, down 0.55% on the day, with a neutral technical signal and bullish moving averages. Support levels are near $760, while resistance sits at $769. The ETF shows no available valuation ratios like P/E or P/B in the data. A dividend of $1.90 is scheduled for payment on July 31, 2026.
Outlook remains mixed amid market volatility from geopolitical tensions and oil price surges. Risks include Fed rate-hike concerns and high valuations, but AI-driven earnings growth offers potential upside. Investors should weigh resilience against near-term headwinds for long-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
